Starting soon: https://cannagather.com/41620

How do Justin Dye and Nirup Krishnamurthy find the time to be CEO and CIO, respectively, at both Medicine Man Technologies and RipKurrent...especially when one is in Colorado while the other is in Florida. Of course being an MDCL shareholder I want their sole focus to be on MDCL. Another thing that concerns me is Justin only posts about RipKurrent on his LinkedIn. At least Nirup has posted MDCL job openings on his.

I was listening to a podcast and they talked about Epidiolex being taken off the drug schedule will allow more doctors to prescribe it. They went on to say that without health insurance a years worth of the drug is a 30K expense. Now I understand why Chris, when talking about DehydraTECH's ability to not only speed up delivery but the potential to decrease health costs...even if paying a royalty, uses GW Pharma when giving hypothetical examples.

Interesting. Thank you.

Pardon the ignorance, just wondering how Marketwatch and Bloomberg shows the market cap of the company as $1.1B while the OTC Markets website has it as $350M? Something doesn't make sense. With 36M outstanding shares, and a stock price around the $10 mark, suggests the OTC markets page is correct...but if that is the case than how does a company with $253M in revenue, for 2019, only have a market cap of $350M?

Proactive Investor interview

Nice level of volume.

Ok. So we all know that the upcoming acquisitions will dilute the stock (calculated by someone here) to 105M shares. In Dec 2019, we as shareholders, voted to allow them to increase their OTC authorized share count to 250M. We all assume that this will be used to onboard other "nation wide" acquisitions...no shareholders is truly a fan of dilution...but if it happens at least we know the max point.

Mic drop...

To me, I thought the best take away from a shareholder perspective, was that they were approved for patents in Australia...and they are using the global patent connection between Australia and the US...they stated that in the upcoming months or quarters they should receive word on whether or not the US accepts Australia's patent approvals.

Well I thought they did a good job presenting...that has never been a weakness for them. Chris and John are extremely knowledgeable in regards to the technology and compliment one another well...Chris the business side and John the lab/medical side. I listened to another presentation and LXRPs was definitely more impressive. Their focus was obvious...appealing to companies in an effort to incorporate DehydraTECH to speed up the company's existing products. I submitted a question that I thought would benefit LXRP in persuading companies...it regarded shelf life and/or temperature changes...but it was overlooked probably due to time constraints.

The presentation count down is in 38 minutes.

All, just a heads up, I went out to https://www.lifesciencesinvestorforum.com/ and logged in. The agenda shows LXRP in the 12EST time slot however if you go to the PRESENTATIONS tab their time is listed from 11-11:30am. Maybe the company operates on Central Time? Just don't want others to miss it.

I honestly thought the presentation seemed like a desperate attempt to get any form of recognition. Like here is our technology...please someone believe in it as much as we do and find a use for it. However the conference is an investor conference...so I guess that is kind of the point in the 20 or so allotted minutes.

https://www.canadiancannabiswire.com/cannabisnewsbreaks/cannabisnewsbreaks-lexaria-bioscience-corp-cse-lxx-otcqx-lxrp-to-participate-in-life-sciences-investor-forums-virtual-conference/

Here is a thought, say it does happen for recreational business...and the medical side turns into delivery only. This might force them into a direction that they were planning on growing sooner rather than later.

It has to be good...they didnt try to hide it under 'other good news'.

There was a 335K bid at 0.23USD...now it is 300K. Makes me think the market expects another dip.

There was an article out today saying a company thinks they have a vaccination...let's hope if they do it will also include DehydraTECH to assist in scaling.

100K ask at $0.30.

Doubled our daily volume by 10am and only 0.08+ to speak for it. Shameful for this low float. Makes you feel like others don't believe the hype will pan out.

All this news and speculation and the ASK just dropped from 0.27 to 0.26.

The question is what would benefit us as shareholders?...I guess anything at this point.

What it tells me is...if Altria goes along with phase 2, wait for the pop, sell some and then buy it back when it drops again after all the excited sell out when they realize that it is just more money toward research...and research takes time, which most shareholders can't accept.

Funny you say this Itchy palm, supposedly, like TP, consumers were stocking up.

Yep, that is my concern. Most of their money is tourist driven.

Jeans, there was an article posted. At this time the Colorado Govenor considered dispensaries 'essential businesses'.

From Proactive News: Lexaria Bioscience Corp, a global innovator in drug delivery platforms has issued share purchase warrants to one of its Canadian-based consultants, entitling the consultant to purchase up to 500,000 common shares. The warrants are exercisable at a price of US$0.30 per share for a period of five years expiring on March 16, 2025. Pursuant to applicable securities laws, the warrants and any shares issued upon exercise thereunder shall bear legends restricting the trade of the same until a period of at least six months from the date of issuance has passed

Didn't they put two? Or was it one one the board and then they hired another one to assist with product development?

All signs pointed up until now with the current stock price...and Chris' comments. I am still adding...and cost averaging down. I feel the only real issue is time...and I am fine with that. Piecing together all of the interviews, it seems like everything that Chris has said is accurate...it is just taking the rest of the industry a very long time to catch up. I hope once they do it doesn't take the industry as long to find Lexaria.

I also think once things finally break, whether it be with the US govt, or other world governments, the industry will be required to adhere to additional regulation surrounding the advertising, product research and testing...which is currently lacking...and this is where DehydraTECH will shine.

Well Bunka's comments didnt exactly instill investor confidence. Meanwhile maybe we don't want Altria to drop phase 2 cash because if they dont then Lexaria is not exclusive to Altria in the US marketplace. Maybe this is a good thing because Lexaria can market to Phillip Morris (with already documented phase 1 research) while at the same time if Altria still wants the technology they still have to adhere to the royalty arrangements of the initial agreement. Right now it is Altria's advantage to lose...and it might happen because of their recent investment failures and a possible tighter pocketbook...but I would like to think that it wont and the delay in moving to phase 2 is just more pressing concerns with Altria (like coronavirus and employee safety). Altria does have 90 days to decide and let's face it the whole agreement of $12M (and just $4M for phase 2) is peanuts in comparison to the JUUL investment. In addition, there is a huge focus over coronoavirus and respiratory concerns. Moving to Lexaria only seems to benefit the company.
...however I also dont work for Altria. I did contact their investor relations...and they directed me to Chris...so who knows where they stand.

Thanks for sharing! Interesting read...still trying to digest it.

https://www.forbes.com/sites/warrenbobrow/2020/03/13/case-mandel-co-founder-of-cannadips-get-busyfive-questions-for-2020/#38d530232266

They will probably continue to plug it...the two of them not only have the initial beverage agreement, for the Hill Street lineup, but also a joint agreement (established this past July, I think) for other 'edible and beverage' products in Canada. This allows Lexy to play the space while still saying that they are not flower touching because everything will be developed at Hill Street's facility (which I think is still awaiting its Health Canada license).

Thanks Abundance. I wasnt thinking about it from that angle. That makes sense.

I am extremely disappointed. I just listened to a 30 minute interview with Peter Barsoom the founder and CEO of Nuka Enterprises and 1906 Chocolates, Cannabis Economy Podcast: Episode 521, which posted yesterday. He spent the first 12 minutes talking about the capabilities of "his tech", in reference to his current/future products, and not a single mention of Lexaria and/or DehydraTECH. What a shame that the company Lexaria touts as their oldest and most revenue generating cannabis license couldn't even give them a mention. What a joke! I went to the 1906 website and looked all over for a something lexaria/DehydraTECH...Nope! Altria...the same thing! Why, with the exception of Cannadips, is this a going theme. (Shoot maybe based on the recent events of Cannadips there-in lies the answer.) I guess as long as Lexaria has money coming in they simply don't care if they are the slightest bit recognized? But seriously, given the success of 1906, their multi-year relationship and the fact that they just expanded their license for 2020...how was Lexaria not being included as part of the packaging negotiated in this deal?

Not to be pessimistic, because I see good things for this company, but I would be interested in seeing how much of the $1.75B in sales last year was due to tourist spent dollars.

So far January retail sales increased from 2019 to 2020 ($99M to $111M) but that was prior to the US corona virus outbreak...which is only gaining traction. When this is all said and done this could have a potentially huge impact on 2020 sales revenue.

Thanks railrider.

It seems to be holding this 1.50's resistance. I am curious as to railrider's take. Maybe it is just me being greedy, if it slips through we may quickly touch the 1.30's.

"Real companies make money even in a growth position."

Awesome find Future! Thanks for sharing!

Beyer, Andy being replaced by Justin Dye was expected. His leaving the company was what shocked me...however the current market cap is because MDCL is still only considered a cannabis consulting company. The bill that is allowing the company to vertically integrate didnt go into effect until Nov 1, 2019. Nov 1st is when MDCL could start to submit their plans to the State to be reviewed...and the State and local govts have 120 days to approve/deny the acquisitions. This is still still a high risk stock because the acquisitions arent official...therefore the company is really only viewed for its 9.4M in revenue last year.